Application of autologous stem cell transplantation in various adult and pediatric rheumatic diseases

Tyndall, Alan

doi:10.1038/pr.2011.66

Cited by 27 publications

(14 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This study revealed that 94.38% of the MSCs were CD90-positive, while only 3.99% were CD34-positive and only 1.71% were CD45-positive, in agreement with a previous study (Tyndall, 2012). However, as no cell-specific surface antigen exits for MSCs, it is necessary to label them with surface antigens to evaluate cell purity and homogeneity (Forostyak et al, 2013;Tan et al, 2013).…”

Section: Discussionsupporting

confidence: 72%

Genetic expression and functional characterization of the RUNX2 gene in human adult bone marrow mesenchymal stem cells

Zhang¹,

Li²

2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Past studies have revealed the critical role of runt-related transcription factor 2 (RUNX2) in the proliferation and differentiation of mesenchymal stem cells (MSCs). This study therefore aimed to investigate the expression profile of the RUNX2 gene in human bone marrow MSCs and its biological characteristics. Bone marrow MSCs were separated from 12 patients who had received hip joint replacement surgery. After purification and culture, the MSCs were subjected to the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, flow cytometry, the alkaline phosphatase assay, reverse transcription polymerase chain reaction, and RUNX2 protein quantification. The cell growth curve, staining images, and information on the membrane antigens and the levels of RUNX2 mRNA and protein were obtained based on the results. The growth curve showed, after a 2-day lag period, cultured MSCs entered into the log phase between d3 (Day 3) and d6, when they reached a plateau. Flow cytometry data suggested 94.38% of MSCs were CD90-positive, while only 3.99 and 1.71% of total cells were positive for CD35 and CD45, respectively. With the elongated induction period, cultured MSCs were polygonal in shape. After a 14-day induction, cell fusion occurred in the center of the cell nodule accompanied by the disappearance of cellular structure to form the calcium nodule, which was stained red. There was also a statistically significant increase in the level of RUNX2 protein at d7 and d14. An osteogenic medium is required for the differentiation of adult MSCs, which is also under RUNX2 regulation. These findings are potentially valuable for clinical practice.

show abstract

Section: Discussionsupporting

confidence: 72%

Genetic expression and functional characterization of the RUNX2 gene in human adult bone marrow mesenchymal stem cells

Zhang¹,

Li²

2015

Genet. Mol. Res.

View full text Add to dashboard Cite

show abstract

“…A phase I study by Duijvestein et al yielded similar results [98]. There a number of studies reporting the usefulness of MSCs in the treatment of autoimmune disorders such as rheumatic diseases, autoimmune encephalomyelitis, multiple sclerosis, and systemic lupus erythematosus (SLE) [99–103]. MSCs are believed to exhibit their immunomodulatory effects through soluble factors [104, 105].…”

Section: Clinical Use and Future Perspectivesmentioning

confidence: 95%

Mesenchymal Stem Cells Isolated from Adipose and Other Tissues: Basic Biological Properties and Clinical Applications

Orbay

Tobita

Mizuno

2012

Stem Cells International

197

137

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) are adult stem cells that were initially isolated from bone marrow. However, subsequent research has shown that other adult tissues also contain MSCs. MSCs originate from mesenchyme, which is embryonic tissue derived from the mesoderm. These cells actively proliferate, giving rise to new cells in some tissues, but remain quiescent in others. MSCs are capable of differentiating into multiple cell types including adipocytes, chondrocytes, osteocytes, and cardiomyocytes. Isolation and induction of these cells could provide a new therapeutic tool for replacing damaged or lost adult tissues. However, the biological properties and use of stem cells in a clinical setting must be well established before significant clinical benefits are obtained. This paper summarizes data on the biological properties of MSCs and discusses current and potential clinical applications.

show abstract

“…The treatment of these disorders takes advantage of the immunomodulatory effects of stem cells, their impact on T lymphocytes and the production of anti-inflammatory cytokines in the place of action. Mesenchymal stem cells can be administered locally, for example, inside a damaged joint, or systemically, because they have the ability to chemotaxis to the place of damage [35,40]. Currently, a few clinical studies have been registered that involve the treatment of rheumatic diseases in patients under the age of 18.…”

Section: Mesenchymal Stem Cells In the Autoimmune Diseasesmentioning

confidence: 99%

Application of mesenchymal stem cells in paediatrics

Wawryk‐Gawda

Wójcik

2017

Current Issues in Pharmacy and Medical Sciences

View full text Add to dashboard Cite

Mesenchymal stem cells (MSC) were described by Friedenstein in the 1970s as being a group of bone marrow non-hematopoietic cells that are the source of fibroblasts. Since then, knowledge about the therapeutic potential of MSCs has significantly increased. MSCs are currently used for the treatment of many diseases, both in adults and children. MSCs are used successfully in the case of autoimmune diseases, including rheumatic diseases, diabetes mellitus type 1, gastroenterological and neurological diseases. Moreover, treatment of such organ disorders as damage or hypoxia through application of MSC therapy has shown to be satisfactory. In addition, there are some types of congenital disorders, including osteogenesis imperfecta and Spinal Muscular Atrophy, that may be treated with cellular therapy. Most studies showed no other adverse effects than fever. Our study is an analysis that particularly focuses on the registered trials and results of MSCs application to under 18 patients with acute, chronic, recurrent, resistance and corticosteroids types of Graft-versus-Host Disease (GvHD). Stem cells currently play an important role in the treatment of many diseases. Long-term studies conducted on animals have shown that cell therapy is both effective and safe. The number of indications for use of these cells in the course of treatment of people is constantly increasing. The results of subsequent studies provide important data justifying the application of MSCs in the course of treatment of many diseases whose treatment is ineffective when utilizing other approaches.

show abstract

Application of autologous stem cell transplantation in various adult and pediatric rheumatic diseases

Cited by 27 publications

References 52 publications

Genetic expression and functional characterization of the RUNX2 gene in human adult bone marrow mesenchymal stem cells

Genetic expression and functional characterization of the RUNX2 gene in human adult bone marrow mesenchymal stem cells

Mesenchymal Stem Cells Isolated from Adipose and Other Tissues: Basic Biological Properties and Clinical Applications

Application of mesenchymal stem cells in paediatrics

Contact Info

Product

Resources

About